ACUTAAS CHEMICALS LTD (ACUTAAS) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of ACUTAAS CHEMICALS LTD ₹610, price ₹3,197, upside -80.9%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Stretched ValuationStrong overvaluation with only moderate quality.
!Fair value ₹609.89 · Strongly overvalued (−80.9%)
✓Quality 60/100
!Expensive Growth(revenue 5y +31.5 %/yr)
✓Highly profitable · 26.4% net margin (TTM)
!Low debt · negative free cash flow
!0.1% dividend yield · Token dividend
!Mixed vs. peers(7/13)
✓Wide moat86/100
!Evidence only low, so the estimate is less certain
Watch ACUTAAS CHEMICALS LTD for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 30, 2026.
How to read this chart
60‑month range ₹399.70 – ₹3,692 · fair‑value band ₹463.19 – ₹756.58 · the ₹3,197 price screens above the ₹609.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 30, 2026.
Follow ACUTAAS CHEMICALS in your weekly email
Every Wednesday you see whether ACUTAAS CHEMICALS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally.
Show more
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.
Stock analysis
ACUTAAS CHEMICALS LTD (ACUTAAS) currently trades at ₹3,197, while our model-based Fair Value estimate is ₹609.89, 80.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹1,486 per share, and 0 of the 17 models we run sit above the ₹3,197 price.
Bear case: the Asset-Based group reads lowest at ₹135.32, and 17 of the 17 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹463.19 (bear) to ₹756.58 (bull), the price of ₹3,197 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
ACUTAAS CHEMICALS LTD reported revenue of ₹13.4B in FY2026 versus ₹5.2B in FY2022, a compound +26.7%/yr. Reported net income was ₹3.6B in FY2026, compounding +49.2%/yr from FY2022.
Key figures
Market cap ₹263B (≈ $2.7B) · P/E ratio 67.8 · P/S ratio 18.0 · EPS (TTM) ₹47.12 · Dividend yield 0.1% · Net margin 26.6% · Return on equity 23.5% · Return on assets (EBIT) 15.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 132% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −39% fair-value upside, at −81%, ACUTAAS screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹22.69 to ₹2,064). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹463.19Fair Value ₹609.89Bull ₹756.58
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹22.49 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+33.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.5%
Start year 2021 (pandemic). Over 10 years: +24.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+22.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.4%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.34.4% vs 27.8%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 33%
2026 sits 280% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 708 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside−80.9% · Bottom 25%
Profitability
Return on equity (TTM)23.5% · Top 25%
Return on assets15.7% · Top 25%
Net margin (TTM)26.4% · Top 25%
Operating margin (TTM)31.3% · Top 25%
Growth and dividend
Revenue growth59.1% · Top 25%
Dividend yield (TTM)0.1% · Bottom 25%
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (TTM)67.8× · Priciest 25%
P/B15.88× · Priciest 25%
P/S (TTM)17.96× · Priciest 25%
EV/EBITDA47.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 41
PAST (return on equity)94· sector 25
HEALTH (low debt)100· sector 95
DIVIDEND (yield)2· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ACUTAAS CHEMICALS LTD (ACUTAAS) overvalued or undervalued?
As of Sep 30, 2026, our model estimates a fair value of ₹609.89 versus a price of ₹3,197, about −81% upside (overvalued).
What is the fair value of ACUTAAS?
Our model-based fair value for ACUTAAS CHEMICALS LTD is ₹609.89 (as of Sep 30, 2026), built from audited fundamentals. The current price: ₹3,197.
What is the quality score of ACUTAAS?
ACUTAAS CHEMICALS LTD has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ACUTAAS CHEMICALS LTD (ACUTAAS)?
Our model-based price target is the fair value of ₹609.89 (as of Sep 30, 2026) from 17 valuation models. Cautious scenario ₹463.19, optimistic scenario ₹756.58. It is a calculation from audited fundamentals, not an analyst target.
What is the ACUTAAS CHEMICALS LTD stock forecast for 2026?
Our models put fair value at ₹609.89, about −81% upside versus a price of ₹3,197 (overvalued). Cautious scenario ₹463.19, optimistic scenario ₹756.58. The calculation is refreshed regularly with new filings.
What is the revenue of ACUTAAS CHEMICALS LTD (ACUTAAS)?
ACUTAAS CHEMICALS LTD reported trailing-twelve-month revenue of about ₹14.6B (latest available figure, as of Sep 30, 2026).
Does ACUTAAS CHEMICALS LTD pay a dividend?
ACUTAAS CHEMICALS LTD currently shows a dividend yield of about 0.08% relative to its recent price (as of Sep 30, 2026).
What is the intrinsic value of ACUTAAS CHEMICALS LTD (ACUTAAS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ACUTAAS CHEMICALS LTD it is ₹609.89 per share (as of Sep 30, 2026), against a price of ₹3,197. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is ACUTAAS CHEMICALS LTD stock overvalued or undervalued in 2026?
As of Sep 30, 2026, ACUTAAS trades above its calculated fair value: price ₹3,197, fair value ₹609.89, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACUTAAS?
No. The price is what the market pays today (₹3,197); the fair value is what the company's own numbers justify (₹609.89). For ACUTAAS CHEMICALS LTD the two are ₹2,587 per share apart. That gap is exactly why we show both numbers side by side.
How much is ACUTAAS CHEMICALS LTD worth?
The market values ACUTAAS CHEMICALS LTD at about ₹263B (market capitalisation, as of Sep 30, 2026). Per share that is ₹3,197; our models calculate a fair value of ₹609.89 per share.
What do the bullish and bearish scenarios say about ACUTAAS?
Our models span a range for ACUTAAS CHEMICALS LTD: cautious scenario ₹463.19, base ₹609.89, optimistic ₹756.58 per share (as of Sep 30, 2026, price ₹3,197). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ACUTAAS?
ACUTAAS CHEMICALS LTD trades at a price-to-earnings ratio of 67.8 (as of Sep 30, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹609.89 is built from several models across several years. Other multiples: P/B 15.9, P/S 18.0, EV/EBITDA 47.9.
How solid is the balance sheet of ACUTAAS CHEMICALS LTD (ACUTAAS)?
Balance-sheet figures for ACUTAAS CHEMICALS LTD (as of Sep 30, 2026): return on equity 23.5%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is ACUTAAS from its 52-week high?
ACUTAAS CHEMICALS LTD trades at ₹3,197, about 13% below its 52-week high of ₹3,692 and 132% above the low of ₹1,380 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹609.89 is for.
Which stocks are comparable to ACUTAAS CHEMICALS LTD?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ACUTAAS CHEMICALS LTD stock attractive at the current price?
The data as of Sep 30, 2026: price ₹3,197, calculated fair value ₹609.89 (−81%), Quality Score 60/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACUTAAS calculated?
We run ACUTAAS CHEMICALS LTD through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹609.89, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. ACUTAAS CHEMICALS LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ACUTAAS CHEMICALS LTD (ACUTAAS)?
The closing price on Oct 1, 2026 was ₹3,197. Our model-based fair value is ₹609.89, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ACUTAAS CHEMICALS LTD right now?
The price sits above even our optimistic bull case (₹756.58). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of ACUTAAS CHEMICALS LTD (ACUTAAS) come from?
Earnings per share at ACUTAAS CHEMICALS LTD grew +25.2 % a year from 2015 to 2026. Broken into its drivers: revenue per share +12.4 %, EBIT margin +11.0 %, tax rate +0.7 %, residual (interest, one-offs) −0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of ACUTAAS CHEMICALS LTD
How large is the market capitalisation of ACUTAAS CHEMICALS LTD (ACUTAAS)?
The market capitalisation of ACUTAAS CHEMICALS LTD is ₹263B (≈ $2.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ACUTAAS CHEMICALS LTD (ACUTAAS)?
The price-to-sales ratio of ACUTAAS CHEMICALS LTD is 18.0 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ACUTAAS CHEMICALS LTD (ACUTAAS)?
Earnings per share at ACUTAAS CHEMICALS LTD are ₹47.12 (price ÷ EPS = P/E 67.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of ACUTAAS CHEMICALS LTD (ACUTAAS)?
The dividend yield of ACUTAAS CHEMICALS LTD is 0.1% (payout 5.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ACUTAAS CHEMICALS LTD (ACUTAAS)?
The net margin of ACUTAAS CHEMICALS LTD is 26.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ACUTAAS CHEMICALS LTD (ACUTAAS)?
The return on equity (ROE) of ACUTAAS CHEMICALS LTD is 23.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ACUTAAS CHEMICALS LTD (ACUTAAS)?
On an EBIT basis the return on assets of ACUTAAS CHEMICALS LTD is 15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ACUTAAS CHEMICALS LTD (ACUTAAS)?
The operating margin of ACUTAAS CHEMICALS LTD is 31.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ACUTAAS CHEMICALS LTD (ACUTAAS)?
Revenue at ACUTAAS CHEMICALS LTD is growing +59.1% versus a year earlier (3y avg +29.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ACUTAAS CHEMICALS LTD (ACUTAAS)?
Earnings per share at ACUTAAS CHEMICALS LTD are growing +67.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ACUTAAS CHEMICALS LTD (ACUTAAS) generate?
The free cash flow of ACUTAAS CHEMICALS LTD is −₹285M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ACUTAAS CHEMICALS LTD (ACUTAAS) hold?
ACUTAAS CHEMICALS LTD holds more cash than debt, ₹1.9B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch ACUTAAS CHEMICALS LTD in the live analysis
One click puts ACUTAAS CHEMICALS LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
